Free tool
FAERS Monitor: Zoryve
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215985 or its brand name (Zoryve, Roflumilast). Reports on generic versions are filed under their own applications.
Reports
3,191
Serious
1,832
57% of reports
Hospitalization
1,067
Death reported
198
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea467
- drug ineffective293
- off label use272
- chronic obstructive pulmonary disease251
- diarrhoea239
- pneumonia229
- asthma215
- cough205
- nausea191
- headache179
- wheezing169
- pruritus161
- therapeutic product effect incomplete160
- weight decreased142
- condition aggravated139
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 178 |
| 2013 | 221 |
| 2014 | 203 |
| 2015 | 76 |
| 2016 | 28 |
| 2017 | 32 |
| 2018 | 73 |
| 2019 | 81 |
| 2020 | 88 |
| 2021 | 100 |
| 2022 | 116 |
| 2023 | 235 |
| 2024 | 398 |
| 2025 | 650 |
| 2026 | 709 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,968 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic obstructive pulmonary diseaseSignal | 251 | 31.9 | 28.3 | 7,453 |
| wheezingSignal | 169 | 18.8 | 16.3 | 2,836 |
| therapeutic product effect incompleteSignal | 160 | 14.9 | 12.8 | 2,056 |
| asthmaSignal | 215 | 12.6 | 11.0 | 2,284 |
| dyspnoeaSignal | 467 | 5.4 | 5.0 | 1,734 |
| coughSignal | 205 | 4.8 | 4.2 | 625 |
| pneumoniaSignal | 229 | 4.7 | 4.1 | 665 |
| weight decreasedSignal | 142 | 3.4 | 2.9 | 235 |
| condition aggravatedSignal | 139 | 3.0 | 2.6 | 188 |
| pruritusSignal | 161 | 2.8 | 2.4 | 182 |
| diarrhoeaSignal | 239 | 2.4 | 2.2 | 208 |
| off label useSignal | 272 | 2.0 | 1.8 | 151 |
| headache | 179 | 1.9 | 1.6 | 75 |
| nausea | 191 | 1.6 | 1.4 | 43 |
| drug ineffective | 293 | 1.5 | 1.3 | 46 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.